Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly Begins a Phase 3 Clinical Trial for a Potential COVID-19 Treatment

By Prosper Junior Bakiny – Jun 15, 2020 at 11:53AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is now running three separate clinical studies of treatment candidates for the novel coronavirus.

On Monday, Eli Lilly (LLY -1.27%) announced that it had begun a phase 3 clinical trial for Olumiant (baricitinib) as a potential treatment for COVID-19. Olumiant is already approved for the treatment of moderate to severe rheumatoid arthritis, and Eli Lilly thinks it could help prevent cytokine storms (a potentially deadly immune reaction) in patients with severe cases of COVID-19. The company also believes that Olumiant could prevent host cells from making more copies of the SARS-CoV-2 virus that causes the disease.

The pharma giant will conduct this study in the U.S. and several other countries in Europe and Latin America. Eli Lilly will enroll 400 hospitalized COVID-19 patients, each of whom will receive daily oral doses of Olumiant (or a placebo) for 14 days, or until they are released from the hospital. The primary endpoint for the trial will be the proportion of patients who die or require intensive care (in the form of mechanical ventilation) when given Olumiant as compared to those who are given a placebo.

Woman on the phone wearing a face mask.

Image Source: Getty Images.

Secondary endpoints for the study include "the proportion of patients with clinical improvement at different time points, time to recovery, duration of hospitalization, number of ventilator-free days and mortality over a 28-day period." Since Olumiant is already approved by regulatory authorities, safety issues aren't a big concern. Eli Lilly said it expects data from this study within a few months. 

Eli Lilly has initiated two other clinical trials for potential COVID-19 treatments. Last week, it announced that it was starting a phase 1 study for an investigational antibody therapy called JS016. Eli Lilly is partnering with Junshi Biosciences, which will run a phase 1 trial for JS016 in China concurrently. This trial will test the safety, tolerability, immunogenicity (the ability to trigger an immune response in the body), and pharmacokinetics (the way the body processes the treatment) in healthy participants who haven't been diagnosed with COVID-19.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$307.50 (-1.27%) $-3.96

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.